CL2021002241A1 - Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570) - Google Patents

Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)

Info

Publication number
CL2021002241A1
CL2021002241A1 CL2021002241A CL2021002241A CL2021002241A1 CL 2021002241 A1 CL2021002241 A1 CL 2021002241A1 CL 2021002241 A CL2021002241 A CL 2021002241A CL 2021002241 A CL2021002241 A CL 2021002241A CL 2021002241 A1 CL2021002241 A1 CL 2021002241A1
Authority
CL
Chile
Prior art keywords
split
restricted
application
binding proteins
activated binding
Prior art date
Application number
CL2021002241A
Other languages
English (en)
Inventor
Anand Panchal
Chad May
Robert B Dubridge
Maia Vinogradova
Original Assignee
Maverick Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverick Therapeutics Inc filed Critical Maverick Therapeutics Inc
Publication of CL2021002241A1 publication Critical patent/CL2021002241A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a construcciones de activación redirigidas biespecíficas convencionales, o COBRA, que se administran en un formato profármaco activo. Tras la exposición a las proteasas tumorales, las construcciones se escinden y activan, de modo que pueden unirse tanto a los antígenos objetivo tumorales (TTA) como a CD3, reclutando así las células T que expresan CD3 al tumor, lo que da como resultado el tratamiento.
CL2021002241A 2017-09-08 2021-08-25 Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570) CL2021002241A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555943P 2017-09-08 2017-09-08
US201762586627P 2017-11-15 2017-11-15
US201762587318P 2017-11-16 2017-11-16

Publications (1)

Publication Number Publication Date
CL2021002241A1 true CL2021002241A1 (es) 2022-04-29

Family

ID=63788010

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2020000570A CL2020000570A1 (es) 2017-09-08 2020-03-06 Proteínas de unión condicionalmente activadas restringidas
CL2021002242A CL2021002242A1 (es) 2017-09-08 2021-08-25 Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
CL2021002241A CL2021002241A1 (es) 2017-09-08 2021-08-25 Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2020000570A CL2020000570A1 (es) 2017-09-08 2020-03-06 Proteínas de unión condicionalmente activadas restringidas
CL2021002242A CL2021002242A1 (es) 2017-09-08 2021-08-25 Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)

Country Status (19)

Country Link
US (5) US11406710B2 (es)
EP (1) EP3679067A2 (es)
JP (3) JP7268005B2 (es)
KR (1) KR20200047687A (es)
CN (1) CN111356700A (es)
AU (3) AU2018328291B2 (es)
BR (1) BR112020004543A2 (es)
CA (1) CA3075034A1 (es)
CL (3) CL2020000570A1 (es)
EC (1) ECSP20021323A (es)
IL (3) IL302613A (es)
MX (1) MX2020002667A (es)
MY (1) MY201723A (es)
PE (1) PE20212205A1 (es)
PH (1) PH12020500474A1 (es)
SG (1) SG11202002089RA (es)
TW (3) TWI812637B (es)
WO (1) WO2019051102A2 (es)
ZA (1) ZA202002325B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302613A (en) 2017-09-08 2023-07-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
CA3102823A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
US20210309756A1 (en) 2018-08-09 2021-10-07 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
WO2020181145A1 (en) * 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens
CN114390938A (zh) 2019-03-05 2022-04-22 武田药品工业有限公司 受约束的条件性活化的结合蛋白
SG11202112541RA (en) * 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
JP7483896B2 (ja) * 2020-01-17 2024-05-15 エショー バイオセラピー， インク． オフターゲット毒性を低下させるプロ抗体
CN114945597A (zh) * 2020-01-17 2022-08-26 艾提欧生物疗法有限公司 降低脱靶毒性的前抗体
CN115968378A (zh) * 2020-06-03 2023-04-14 明尼苏达大学董事会 靶向b7h3的蛋白质及其使用方法
CA3185968A1 (en) * 2020-07-13 2022-01-20 Tony Lahoutte Antibody fragment against folr1
TW202214707A (zh) 2020-08-17 2022-04-16 美商馬弗瑞克療法公司 約束條件活化之結合蛋白
WO2022051647A2 (en) * 2020-09-04 2022-03-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding protein constructs with human serum albumin domains
MX2023006817A (es) 2020-12-09 2023-08-14 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
WO2022130013A1 (en) 2020-12-14 2022-06-23 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
WO2022212668A1 (en) * 2021-03-31 2022-10-06 Heat Biologics, Inc. Methods and compositions related to tnfrsf25/dr3 agonists
JP2024513099A (ja) * 2021-04-06 2024-03-21 武田薬品工業株式会社 制約され、条件付きで活性化される結合タンパク質を使用する治療方法
AR128593A1 (es) * 2022-02-23 2024-05-22 Takeda Pharmaceuticals Co Proteínas de unión condicionalmente biespecíficas
WO2023212662A2 (en) * 2022-04-28 2023-11-02 Oregon Health & Science University Compositions and methods for modulating antigen binding activity

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
PT797676E (pt) 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
NZ507381A (en) 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU2001283496A1 (en) 2000-07-25 2002-02-05 Immunomedics, Inc. Multivalent target binding protein
EP1354600A1 (en) 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
DE10231109A1 (de) 2002-07-10 2004-01-22 Daimlerchrysler Ag Abgasturbine
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
US20100003253A1 (en) 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
CA2542239C (en) 2003-10-16 2014-12-30 Micromet Ag Multispecific deimmunized cd3-binders
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
CA2624781A1 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies tm and polypeptides against egfr and igf-ir
RU2008129827A (ru) 2005-12-21 2010-01-27 МЕДИММЬЮН, ЭлЭлСи (US) МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
JP5485152B2 (ja) * 2007-08-15 2014-05-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 単一特異性および多特異性抗体ならびに使用方法
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
AU2010242830C1 (en) 2009-05-01 2014-02-13 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20110029476A1 (en) 2009-07-29 2011-02-03 Kas Kasravi Indicating relationships among text documents including a patent based on characteristics of the text documents
WO2011033105A1 (en) * 2009-09-18 2011-03-24 Micromet Ag Dosage regimen for administering an epcamxcd3 bispecific antibody
SG185354A1 (en) * 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
US9193791B2 (en) 2010-08-03 2015-11-24 City Of Hope Development of masked therapeutic antibodies to limit off-target effects
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
BR122016016837A2 (pt) 2011-05-21 2019-08-27 Macrogenics Inc moléculas de ligação a cd3; anticorpos de ligação a cd3; composições farmacêuticas; e usos da molécula de ligação a cd3
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
EA027160B1 (ru) 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
UY34504A (es) * 2011-12-09 2013-06-28 Amgen Res Munich Gmbh Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3
RS56773B1 (sr) 2012-01-13 2018-04-30 Univ Wuerzburg J Maximilians Dvojna bipartitna funkcionalna komplementacija izazvana antigenom
MX349192B (es) 2012-02-27 2017-07-18 Boehringer Ingelheim Int Polipeptidos de union a cx3cr1.
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
MX353382B (es) 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
RU2713121C2 (ru) 2012-04-27 2020-02-03 Сайтомкс Терапьютикс, Инк. Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения
AU2013278075B2 (en) 2012-06-22 2018-05-17 Cytomx Therapeutics, Inc. Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN105189544A (zh) 2013-04-19 2015-12-23 科瓦根股份公司 具有抗肿瘤活性的新颖的双特异性结合分子
US9517276B2 (en) 2013-06-04 2016-12-13 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
WO2014201021A2 (en) 2013-06-10 2014-12-18 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells
EP3024851B1 (en) 2013-07-25 2018-05-09 CytomX Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
CN107108738A (zh) 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
AU2015294834B2 (en) 2014-07-31 2021-04-29 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
WO2016033225A2 (en) 2014-08-27 2016-03-03 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
CA2959141A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
MX2017003847A (es) * 2014-09-25 2017-12-15 Amgen Inc Proteinas biespecificas activables por proteasas.
CN107646039B (zh) * 2015-04-02 2022-04-15 埃博灵克斯股份有限公司 具有有效抗hiv活性的双特异性cxcr4-cd4多肽
JP2018520642A (ja) 2015-05-01 2018-08-02 ジェネンテック， インコーポレイテッド マスク抗ｃｄ３抗体及びその使用方法
IL292798A (en) * 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
PL3294768T3 (pl) * 2015-05-13 2020-03-31 Ablynx N.V. Polipeptydy rekrutujące komórki T oparte na reaktywności TCR alfa/beta
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US20190002563A1 (en) * 2015-08-17 2019-01-03 Macrogenics, Inc. Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof
WO2017085149A1 (en) 2015-11-16 2017-05-26 Fuji Seal International, Inc. Method and system for forming sleeved containers
WO2017087789A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
WO2017156178A1 (en) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use
SG11201810327XA (en) 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single domain serum albumin binding protein
BR112018073761A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteínas de ligação ao cd3 de fragmento variável de cadeia única
CN106632681B (zh) 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
WO2018071777A1 (en) 2016-10-14 2018-04-19 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
WO2018160671A1 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Targeted checkpoint inhibitors and methods of use
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
AU2018250641A1 (en) 2017-04-11 2019-10-31 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
IL302613A (en) 2017-09-08 2023-07-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
EP3679068A2 (en) 2017-09-08 2020-07-15 Maverick Therapeutics, Inc. CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS
SG11202011330PA (en) 2018-05-14 2020-12-30 Harpoon Therapeutics Inc Binding moiety for conditional activation of immunoglobulin molecules
US20210284728A1 (en) 2018-05-14 2021-09-16 Harpoon Therapeutics, Inc. Dual binding moiety
WO2019222282A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
CN113286811A (zh) 2018-07-30 2021-08-20 南加利福尼亚大学 改善过继性细胞疗法的效力和安全性
US20210309756A1 (en) 2018-08-09 2021-10-07 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
US20220017626A1 (en) 2018-09-21 2022-01-20 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
EP3954707A1 (en) 2018-12-21 2022-02-16 Zhejiang Shimai Pharmaceutical Co., Ltd. Protease cleavable bispecific antibodies and uses thereof
CN114390938A (zh) 2019-03-05 2022-04-22 武田药品工业有限公司 受约束的条件性活化的结合蛋白
WO2020181145A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens
CA3138854A1 (en) 2019-05-02 2020-11-05 The General Hospital Corporation Teac and attac immunooncology compositions and methods

Also Published As

Publication number Publication date
TW202332689A (zh) 2023-08-16
CL2020000570A1 (es) 2021-03-12
US11744892B2 (en) 2023-09-05
ECSP20021323A (es) 2020-07-31
AU2023200434A1 (en) 2023-03-02
PH12020500474A1 (en) 2021-01-25
US20240139317A1 (en) 2024-05-02
CL2021002242A1 (es) 2022-04-29
AU2018328291B2 (en) 2022-10-27
KR20200047687A (ko) 2020-05-07
US20220273794A1 (en) 2022-09-01
WO2019051102A3 (en) 2019-05-23
TWI823811B (zh) 2023-11-21
TW201920244A (zh) 2019-06-01
AU2018328291A1 (en) 2020-04-23
JP7268005B2 (ja) 2023-05-02
IL302614A (en) 2023-07-01
US20220273795A1 (en) 2022-09-01
EP3679067A2 (en) 2020-07-15
CN111356700A (zh) 2020-06-30
BR112020004543A2 (pt) 2020-09-08
CA3075034A1 (en) 2019-03-14
JP7490853B2 (ja) 2024-05-27
IL273119B1 (en) 2023-06-01
JP2020537496A (ja) 2020-12-24
MX2020002667A (es) 2020-08-03
MY201723A (en) 2024-03-14
WO2019051102A2 (en) 2019-03-14
AU2023200437A1 (en) 2023-03-02
US11744893B2 (en) 2023-09-05
SG11202002089RA (en) 2020-04-29
JP2024105561A (ja) 2024-08-06
PE20212205A1 (es) 2021-11-18
TW202426489A (zh) 2024-07-01
US11406710B2 (en) 2022-08-09
IL273119A (en) 2020-04-30
IL302613A (en) 2023-07-01
JP2023093632A (ja) 2023-07-04
ZA202002325B (en) 2023-10-25
US20190076524A1 (en) 2019-03-14
TWI812637B (zh) 2023-08-21
US20230414752A1 (en) 2023-12-28
IL273119B2 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
CL2021002242A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
UY37829A (es) Muteínas de interleucina 21 y métodos de tratamiento
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
CU20170169A7 (es) Anticuerpos de factor xi
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
MX2020004712A (es) Vesiculas extracelulares modificadas geneticamente con proteinas.
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
ECSP23018458A (es) Proteínas de unión restringidas activadas de forma condicional
DE602006014009D1 (de) Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
CO2023009342A2 (es) Proteínas de unión condicionalmente biespecíficas
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
BR112022002236A2 (pt) Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas